ReviewWorld journal of surgical oncology2020
Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature.
Review in World journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Comparison of Perioperative and Oncologic Outcomes Between Robotic and Open Retroperitoneal Lymph Node Dissection in Testicular Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Pooled it
- Robotic assisted versus non-robotic retroperitoneal lymph node dissection for testicular cancer: an updated systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Radiological lymphoceles and clinically relevant lymphatic complications after retroperitoneal lymph node dissection for testicular cancer: a longitudinal imaging study.Abdominal radiology (New York) · 2026Article
- Is radiotherapy still an option for residual retroperitoneal masses in stage IIC seminoma?Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Robotic versus open post-chemotherapy retroperitoneal lymph node dissection: a propensity score matched study across 11 academic medical centers.World journal of urology · 2026Article
- Robotic retroperitoneal lymph node dissection: a stepwise technical guide.Journal of robotic surgery · 2026Article
- [Retroperitoneal lymphadenectomy in the treatment of testicular germ cell tumors-Is the robot-assisted technique superior to the open surgical approach?]Urologie (Heidelberg, Germany) · 2025Review
- The perioperative outcomes of retroperitoneal lymph node dissection in Germany for patients with testicular cancer: Results from the GRAND study.International journal of cancer · 2025Article
- Management of Refractory Chylous Ascites.Urology case reports · 2025Article
- Robotic Retroperitoneal Lymph Node Dissection for Testicular Cancer-First Experience and Learning Curve of a Single Surgeon.Cancers · 2025Article
- Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Testicular Cancer at a National Referral Centre.Cancers · 2025Article
- Implementing High-Quality Retroperitoneal Lymph Node Dissection for Testicular Cancer at an Australian Tertiary Hospital: Challenging the Centralisation Paradigm in High-Need Areas.Research and reports in urology · 2025Article
- Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience.European urology open science · 2024Article
- Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Current oncology reports · 2024Review
- Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer.Asian journal of urology · 2024Article
- Radiomics Analyses to Predict Histopathology in Patients with Metastatic Testicular Germ Cell Tumors before Post-Chemotherapy Retroperitoneal Lymph Node Dissection.Journal of imaging · 2023Article
- Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases.World journal of urology · 2023Article
- Postchemotherapy robotic retroperitoneal lymph node dissection for non-seminomatous germ cell tumors in the lateral decubitus position: oncological and functional outcomes.World journal of urology · 2023Article
- Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center.Medicina (Kaunas, Lithuania) · 2023Review
- The Role of CT in the Staging and Follow-Up of Testicular Tumors: Baseline, Recurrence and Pitfalls.Cancers · 2022Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-chemotherapy retroperitoneal lymph node dissection (pc-RPLND) is one cornerstone in the clinical management of patients with nonseminomatous testicular germ cell tumours (GCT). A wide range of complication rates in this type of surgery is reported so far. We retrospectively evaluated the frequency of major complications by using the Clavien-Dindo classification and analysed the influence of various clinical factors on complication rates in pc-RPLND.
methodsWe retrospectively analysed 146 GCT patients undergoing pc-RPLND. Complications of grade III-V according to the Clavien-Dindo classification occurring within 30 days after surgery were registered along with the following clinical factors: age, body mass index (BMI), duration of surgery, number of anatomic fields resected, side of primary tumour, histology of surgical specimen, histology of primary tumour, and total dose of cisplatin applied prior to surgery. For comparison, we also evaluated 35 chemotherapy-naïve patients with primary RPLND and 19 with laparoscopic RPLND. We analysed types and frequencies of the various complications as well as associations with clinical factors using descriptive statistical methods.
resultsA total of 14.4% grade III-IV complications were observed in pc-RPLND, and 8.6% and 5.3% in primary and in laparoscopic RPLND, respectively. There was no perioperative mortality. Lymphocele was the most frequent adverse event (16% of grade III-IV complications). Operation time > 270 min (p = 0.001) and vital cancer in the resected specimen (p = 0.02) were significantly associated with higher complication rates. Left-sided resection fields involved two-fold higher complication rates, barely missing statistical significance (p = 0.06).
conclusionsPc-RPLND involves a grade III-V complication rate of 14.4%. Prolonged operation time and vital cancer in the residual mass are significantly associated with higher complication rates. The Clavien-Dindo classification system may allow inter-observer variation in rating complication grades, which may represent one reason for the wide range of reported RPLND complication rates. RPLND represents major surgery and surgeons active in this field must be competent to manage adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.